● AI Equity Research · Healthcare

Edwards Lifesciences Corporation (EW)

AI stock analysis · Medical Devices · Last analyzed Aug 18, 2026

Compass Score

3.0/5

Call

Hold

Price

$90.81

AI Target

$100.96 +11.2%

AI Analyst Summary

Edwards Lifesciences is a structurally compelling pure-play in structural heart disease and critical care monitoring, with 13.6% revenue growth reflecting durable procedure volume expansion in TAVR and other cardiac therapies. The forward P/E of 26.9x implies the market anticipates a sharp earnings recovery, supported by strong analyst conviction (21 Buys, 0 Sells). The primary risk is that the 25.4% trailing EPS decline — likely tied to portfolio restructuring — takes longer than expected to reverse, leaving the elevated trailing multiple exposed if growth disappoints.

Catalysts

TAVR volume acceleration: upcoming quarterly results could demonstrate continued double-digit TAVR procedure growth in the U.S. and Europe, validating the revenue trajectory and supporting earnings recovery.
Earnings normalization in H2: as one-time charges and divestiture impacts roll off, forward EPS estimates of ~$2.80–$3.00 could be reaffirmed or raised, compressing the forward P/E and re-rating the stock.
Pipeline milestones: FDA decisions or clinical data readouts on next-generation transcatheter heart valve platforms (e.g., EVOQUE tricuspid or SAPIEN expansion) could expand the addressable market and drive upward analyst target revisions.

Fundamentals

Pe Trailing P/E 54.7x / Forward P/E 26.9x · 2.0/5

Trailing P/E of 54.7x is elevated relative to the broader healthcare/medical devices sector median. The forward P/E of 26.9x suggests meaningful earnings recovery ahead, but the current multiple leaves little room for error and reflects a premium valuation not yet justified by trailing results.

Peg PEG 2.20 · 2.0/5

A PEG of 2.20 sits in the above-average but not egregious range. However, with trailing earnings down sharply YoY, the growth denominator is questionable in the near term, making the PEG less reliable as a value signal.

Analyst Rating Buy consensus (1.6) · 4.0/5

Consensus rating of 1.6 maps to a strong Buy signal across 26 analysts, with 21 Buys and 7 Holds and no Sell ratings. Broad analyst conviction is constructive despite near-term earnings headwinds.

Earnings Trend EPS -25.4% YoY / Revenue +13.6% YoY · 2.0/5

Trailing EPS declined 25.4% YoY, a meaningful deterioration that weighs heavily on the score. Revenue growth of 13.6% is encouraging and suggests underlying demand is intact, but the earnings contraction — likely driven by divestitures or cost pressures — is a significant headwind that cannot be ignored.

Price Target Beat 3 of 4 quarters beat (limited history provided) · 3.0/5

EPS beat in 3 of the last 4 quarters is in line with expectations. Only 4 quarters of data are available, so per guidelines this is scored as 3 (neutral). Management has demonstrated reasonable execution but not a standout track record on beats.

Management Mixed execution; divestiture-driven earnings disruption · 3.0/5

Revenue growth of 13.6% signals effective commercial execution, but the 25.4% EPS decline suggests earnings quality issues — possibly tied to portfolio restructuring. Beat rate is adequate but not exceptional. Analyst confidence is high, tempering the concern, but management scores neutral pending earnings stabilization.

● See the full picture

Get today's top-scored picks, ranked for you.

Compass screens thousands of stocks every morning and hands you a short list of high-conviction picks — scored, explained, and re-ranked to your risk profile.

Start free for 3 days →

No credit card. Then $9/month. Cancel anytime.

How Compass scores stocks

Compass pre-filters thousands of U.S. equities by fundamentals, then an AI analyst scores each finalist 1–5 across six measures — spanning valuation, growth, analyst sentiment, and management quality — into one composite score, refreshed every market morning. Browse all covered stocks →

Not financial advice. Compass is an analytical tool, not a registered investment adviser or broker-dealer. Scores and recommendations are generated by AI, may be inaccurate or out of date, and are not investment, financial, legal, or tax advice. Investing involves risk, including loss of principal. Do your own research and consult a licensed financial professional. About Compass.